EVAXION BIOTECH A/S |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.7 USD | -0.54% |
|
-5.37% | -46.04% |
| 05:14pm | European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher | MT |
| May. 06 | European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading | MT |
Presentation Operator MessageOperator (Operator)Greetings and welcome to the Evaxion Corporate...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Evaxion Biotech A/S is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
Calendar
2024-05-29
- Nordic Digital Science & Innovation Day
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
3.72
USD
Average target price
11.75
USD
Spread / Average Target
+215.86%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -46.04% | 20.13M | |
| +27.37% | 44.96B | |
| +0.06% | 42.65B | |
| +46.00% | 41.85B | |
| -5.31% | 29.04B | |
| +10.06% | 26.08B | |
| -21.08% | 19.03B | |
| +6.34% | 12.75B | |
| +28.75% | 12.06B | |
| -3.60% | 11.75B |
- Stock Market
- Equities
- EVAX Stock
- News Evaxion Biotech A/S
- Transcript : Evaxion Biotech A/S, Q4 2022 Earnings Call, Apr 27, 2023